In clinical studies several classes of HDAC inhibitors demonstrated potent anticancer activities with remarkable tumor specificity, such as cutaneous T-cell lymphoma and peripheral T-cell lymphoma [26,27,28,29]. The gene discussed is HDAC9; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.